A high-throughput hybridoma selection method using fluorometric microvolume assay technology

Journal of Biomolecular Screening

Volumn 13, Issue 3, 2008, Pages 210-217

  Lee, Rozanne ^a,b   Tran, Mylinh ^a   Nocerini, Mark ^a,c   Liang, Meina ^a,d  

^a AMGEN INC   (United States)

^b Medarex Inc   (United States)

^c M Biotech Inc   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Cell based antibody binding assay; Fluorometric microvolume assay technology; FMAT; High throughput; Hybridoma selection; Monoclonal antibody

Indexed keywords

MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY;

ANTIBODY DETECTION; ANTIGEN ANTIBODY REACTION; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CELL SURFACE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUOROMETRIC MICROVOLUME ASSAY TECHNOLOGY; FLUOROMETRY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HYBRIDOMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ANTIBODIES; ANTIBODY SPECIFICITY; BIOLOGICAL ASSAY; CELL LINE, TUMOR; FLUOROMETRY; HUMANS; HYBRIDOMAS; RECEPTORS, CELL SURFACE;

EID: 40049097990     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057108314148     Document Type: Article

References (14)

1. Weiner LM: An overview of monoclonal antibody therapy of cancer. Semin Oncol 1999 ; 26: 41-50.
2. Reichert JM: Monoclonal antibodies in the clinic. Nat Biotechnol 2001 ; 19: 819-822.
3. Weinberg WC, Frazier-Jessen MR, Wu WJ, Weir A., Hartsough M., Keegan P.,, et al. Development and regulation of monoclonal antibody products: challenges and opportunities. Cancer Metastasis Rev 2005 ; 24: 569-584.
4. Kohler G., Milstein S.: Continuous culture of fused cells secreting antibody of redefined specificity. Nature 1975 ; 256: 495.
5. Mendez MJ, Green LL, Corvalan Jrf, Jia XC, Maynard Currie CE, Yang XD,, et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genetics 1997 ; 15: 146-156.
6. Jakobovits A.: The long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice. Exp Opin Invest Drugs 1998 ; 7: 607-614.
7. Davis CG, Gallo ML, Corvalan Jrf: Transgenic mice as a source of fully human antibodies for the treatment of cancer. Cancer Metastasis Rev 1999 ; 18: 421-425.
8. Kellermann SA, Green LL: Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics. Curr Opin Biotechnol 2002 ; 13: 593-597.
9. Mellentin-Michelotti J., Evangelista LT, Swartzman EE, Miraglia SJ, Werner WE, Yuan PM: Determination of ligand binding affinities for endogenous seven-transmembrane receptors using fluorometric microvolume assay technology. Anal Biochem 1999 ; 272: 182-190.
10. Miraglia S., Swartzman EE, Mellentin-Michelotti J., Evangenista L., Smith C., Gunawan I.,, et al. Homogeneous cell- and bead-based assays for high throughput screening using fluorometric microvolume assay technology. J Biomol Screening 1999 ; 4: 193-204.
11. Yang XD, Jia XC, Corvalan Jrf, Wang P., Davis CG, Jakobovits A.: Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999 ; 59: 1236-1243.
12. Yang XD, Jia XC, Corvalan Jrf, Wang P., Davis CG: Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol/Hematol 2001 ; 38: 17-23.
13. Reilly RM, Kiarash R., Sandhu J., Lee YW, Cameron RG, Hendler A.,, et al. A comparison of EGF and Mab 528 labeled with 111In for imaging human breast cancer. J Nucl Med 2000 ; 41: 903-911.
14. Zhang JH, Chung Tdy, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screening 1999 ; 4: 67-73.